Beyond the Standard: Individualized Approaches to Dual Antiplatelet Therapy Gain Attention
Dirk Sibbing, Professor, Cardiologist and Angiologist at Privatklinik Lauterbacher Mühle and LMU Munich, shared an insightful post on LinkedIn:
”When it comes to dual antiplatelet treatment we are still using a non-individualized approach in our everyday clinical practice for patients after PCI.
However, evidence is accumulating that sex, age, BMI and many more variables may constitute relevant treatment effect modifiers for drugs like clopidogrel, prasugrel or ticagrelor.
See the latest data on DAPT and sex in the European Heart Journal and my Editorial that puts the findings into perspective.”
Read the full article here.
Article: Dual antiplatelet therapy modulation strategies beyond standard of care: a promising path towards individualized antiplatelet treatment
Author: Dirk Sibbing
Stay updated on all science in the field of hematology with Hemostasis Today.
-
Nov 6, 2025, 08:24Jacqui McCallum Reflects on Meeting with The Royal Melbourne Hospital Stroke and Neurology Ward Team
-
Nov 6, 2025, 08:17Maxime Dely: The True Heroes of Blood Donation Are Them!
-
Nov 6, 2025, 07:11Francesco Giurazza on Radial Access for Liver Transarterial Chemoembolization
-
Nov 6, 2025, 07:04Andrea Van Beek: Proud to be a Certified Anticoagulation Care Provider (CACP)!
-
Nov 6, 2025, 06:57Jian-Ke Tie’s Team on Comorbidity of VitK-dependent Clotting Factors Deficiency and Chondrodysplasia Punctata
-
Nov 6, 2025, 04:17Aakanksha A To Present Insights from ASH Education Social Media Initiative at 67th ASH Meeting
-
Nov 6, 2025, 04:03Yaping Zhang on Two-Way GPIb-IX Signaling in Platelet Activation and VWF Binding
-
Nov 6, 2025, 03:38Thierry Burnouf on Platelet-Derived Extracellular Vesicles and Their Role in Neurogenesis
-
Nov 6, 2025, 03:29Shubham Misra to Present 3 Abstracts at International Stroke Conference 2026